Prevalence of selective inhibition of HPV-16 DNA amplification in cervicovaginal lavages

HPV‐16 viral load has been assessed with real‐time PCR assays by measuring HPV‐16 DNA and a human gene in genital samples. HPV‐16 viral load measurements are thus based on the inference that inhibitors contained in samples will equally impede amplification of DNA sequences from HPV‐16 and human DNA....

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 72; no. 1; pp. 132 - 137
Main Authors Lefevre, Jonas, Hankins, Catherine, Pourreaux, Karina, Voyer, Hélène, Coutlée, François
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2004
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:HPV‐16 viral load has been assessed with real‐time PCR assays by measuring HPV‐16 DNA and a human gene in genital samples. HPV‐16 viral load measurements are thus based on the inference that inhibitors contained in samples will equally impede amplification of DNA sequences from HPV‐16 and human DNA. We have previously shown that sample lysates can inhibit amplification of HPV‐16 but not β‐globin DNA. In the current study, cervicovaginal lavages lysates considered adequate for PCR analysis by a qualitative β‐globin PCR test, were screened for the presence of inhibitors using internal controls (IC) for HPV‐16 DNA and β‐globin in real‐time PCR assays. Of 150 lysates screened with both ICs, 12 (8%) contained inhibitors. Inhibition of amplification of both ICs was demonstrated in four of these specimens. In eight lysates, amplification of HPV‐16 IC only was impeded. Six (50%) of these 12 lysates tested positive for HPV‐16 DNA despite the presence of PCR inhibitors. The HPV‐16 viral load increased significantly after dilution of 11 of 12 lysates, demonstrating the presence of inhibitors in the undiluted lysate. Nine (90%) of 10 samples with inhibitors that were tested after dilution did not demonstrate inhibitory activity. The use of internal controls in real‐time PCR is clearly essential to determine HPV viral loads since the effect of inhibitors on primer‐driven genomic amplification is variable. J. Med. Virol. 72:132–137, 2004. © 2004 Wiley‐Liss, Inc.
Bibliography:The Canadian Institutes of Health Research (supports The Canadian Women's HIV Study)
ArticleID:JMV10539
Fonds de la Recherche en Santé du Québec (to FC, who is a chercheur national)
CANFAR
istex:5E9108D79502E33D408701B2E21664E837CFFA2D
ark:/67375/WNG-4FF4SQVH-3
The Canadian Women's HIV Study Group includes the following investigators from across Canada: Principal Investigator: Catherine Hankins. Halifax: Janet Conners*, Rob Grimshaw, David Haase, Lynn Johnston*, Wally Schlech*, Arlo Yuzicappi‐Fayant*. Hamilton: Stephen Landis, Fiona Smaill*, Marek Smieja. Kingston: Wendy Wobeser*, Peter Ford. London: Ole Hammerberg, Ted Ralph, Bill Thompson*. Montréal: François Coutlée*, Julian Falutz, Alex Ferenczy*, Marina Klein*, Louise Labrecque, Richard Lalonde, Grégoire Noël*, Chantal Perron*, Jean‐Pierre Routy, and Emil Toma. Ottawa: Claire Touchie. Québec: Louise Coté, Hélène Senay, Sylvie Trottier*. Saskatoon: Kurt Williams*. Sherbrooke: Louise Dion, Alain Piché. Sudbury: Roger Sandre. Toronto: Louise Binder*, Donna Keystone, Anne Phillips, Anita Rachlis*, Irving Salit, Cheryl Wagner, Sharon Walmsley*. Vancouver: Paula Braitstein*, David Burdge*, Marianne Harris, Deborah Money*, Julio Montaner*. *are co‐investigators.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.10539